Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levobupivacaine PVB vs PECS 2 in Breast Cancer Surgery
NCT05816538Active, not recruiting
- Sponsor
- University of Rijeka
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of levobupivacaine in breast cancer (2 arms), sponsored by University of Rijeka. Primary endpoints: Change in measured serum cytokines (IL-1, IL-6, TNF-alpha, IL-10) and Change in cell number of individual lymphocyte subpopulations. Started Jan 2024; status: active, not recruiting.
02
Drugs
levobupivacaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05816538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816538.